
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
San Francisco--An investigational selective alpha-1 adrenoreceptor blocker improves both the obstructive symptoms associated with BPH and symptoms associated with overactive bladder, according to a Japanese study presented at the AUA annual meeting here.





